Stephen Poor - Concepedia

Author

Stephen Poor

Novartis (United States)ORCID

Also Known As

S. Poor, Samad Nazar Poor, Seyed Mostafa Baghaei Poor, Stephen H. Poor, Stephen Poor

Publications

569

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)University College London University of Bonn Roche (Switzerland)

About

Stephen Poor is an author at Novartis (United States) specializing in drug discovery, ophthalmology, and glaucoma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	65
2	Pharmacology	2	2	65
3	Drug Discovery	2	2	65
4	Medicinal Chemistry	1	1	36
5	Molecular Pharmacology	1	1	36

Stephen Poor

Publications

499

Citations

H-Index

Page 1

	Year	Citations
Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation Stephen Poor, Yubin Qiu, Elizabeth Fassbender, Investigative Ophthalmology & Visual Science	2014	72
Risk Segmentation Related to the Offering of a Consumer‐Directed Health Plan: A Case Study of Humana Inc. Laura Tollen, Murray N. Ross, Stephen Poor Health Services Research	2004	66
Long-acting protein drugs for the treatment of ocular diseases Joy G. Ghosh, Andrew Nguyen, Chad E. Bigelow, Nature Communications	2017	54
A proteogenomic signature of age-related macular degeneration in blood Valur Emilsson, Elías F. Guðmundsson, Brynjolfur G. Jonsson, Nature Communications	2022	44
The Discovery of <i>N</i>-(1-Methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1<i>H</i>-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration Christopher M. Adams, Karen Anderson, Gerald D. Artman, Journal of Medicinal Chemistry Ocular DiseaseChoroidal NeovascularizationPharmacotherapyRetinal TherapiesOcular Pharmacology	2018	36
Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration John Demirs, Junzheng Yang, Maura Crowley, Investigative Ophthalmology & Visual Science	2021	32
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration Erik L. Meredith, Nello Mainolfi, Stephen Poor, Journal of Medicinal Chemistry Translational MedicineOcular DiseaseOphthalmologyProlonged Ocular RetentionWet Amd Patients	2015	29
Characteristics and Spatial Distribution of Structural Features in Age-Related Macular Degeneration Marlene Saßmannshausen, Charlotte Behning, Jonas Weinz, Ophthalmology Retina	2022	27
Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration Hannah Dunbar, Charlotte Behning, Amina Abdirahman, JAMA Ophthalmology	2022	21
Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report Marlene Saßmannshausen, Charlotte Behning, Ben Isselmann, Scientific Reports	2022	21

Page 1